These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 20922572)

  • 61. Clinical utilization of chemokines to combat cancer: the double-edged sword.
    Dell'Agnola C; Biragyn A
    Expert Rev Vaccines; 2007 Apr; 6(2):267-83. PubMed ID: 17408375
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tumor-associated macrophages: implications in cancer immunotherapy.
    Petty AJ; Yang Y
    Immunotherapy; 2017 Mar; 9(3):289-302. PubMed ID: 28231720
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death.
    Chouaib S; Thiery J; Gati A; Guerra N; El Behi M; Dorothée G; Mami-Chouaib F; Bellet D; Caignard A
    Tissue Antigens; 2002 Oct; 60(4):273-81. PubMed ID: 12472656
    [TBL] [Abstract][Full Text] [Related]  

  • 64. T-regulatory cells: key players in tumor immune escape and angiogenesis.
    Facciabene A; Motz GT; Coukos G
    Cancer Res; 2012 May; 72(9):2162-71. PubMed ID: 22549946
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Dormancy of tumor cells].
    Strien L; Joensuu K; Heikkilä P
    Duodecim; 2013; 129(21):2245-52. PubMed ID: 24340675
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [At the crossroads of cancer].
    Chouaib S
    Bull Cancer; 2013 Jun; 100(6):569-74. PubMed ID: 23735599
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role of p53 in the sensitization of tumor cells to apoptotic cell death.
    Thiery J; Echchakir H; Dorothée G; Ameyar-Zazoua M; Haddada H; Mami-Chouaib F; Chouaib S
    Mol Immunol; 2002 May; 38(12-13):977-80. PubMed ID: 12009576
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunotherapy of cancer: targeting cancer during active disease or during dormancy?
    Shah SA; Zarei M; Manjili SH; Guruli G; Wang XY; Manjili MH
    Immunotherapy; 2017 Sep; 9(11):943-949. PubMed ID: 29338608
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
    Galluzzi L; Buqué A; Kepp O; Zitvogel L; Kroemer G
    Cancer Cell; 2015 Dec; 28(6):690-714. PubMed ID: 26678337
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Escape from host-antitumor immunity.
    Pawelec G; Zeuthen J; Kiessling R
    Crit Rev Oncog; 1997; 8(2-3):111-41. PubMed ID: 9570292
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anti-angiogenesis: making the tumor vulnerable to the immune system.
    Griffioen AW
    Cancer Immunol Immunother; 2008 Oct; 57(10):1553-8. PubMed ID: 18438662
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High intensity focused ultrasound ablation and antitumor immune response.
    Wu F
    J Acoust Soc Am; 2013 Aug; 134(2):1695-701. PubMed ID: 23927210
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The immune contexture in cancer prognosis and treatment.
    Fridman WH; Zitvogel L; Sautès-Fridman C; Kroemer G
    Nat Rev Clin Oncol; 2017 Dec; 14(12):717-734. PubMed ID: 28741618
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings.
    Goruganthu MUL; Shanker A; Dikov MM; Carbone DP
    Front Immunol; 2020; 11():1958. PubMed ID: 32922403
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A review of mathematical models of cancer-immune interactions in the context of tumor dormancy.
    Wilkie KP
    Adv Exp Med Biol; 2013; 734():201-34. PubMed ID: 23143981
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CD4 and CD8 T lymphocyte interplay in controlling tumor growth.
    Ostroumov D; Fekete-Drimusz N; Saborowski M; Kühnel F; Woller N
    Cell Mol Life Sci; 2018 Feb; 75(4):689-713. PubMed ID: 29032503
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunological responses can have both pro- and antitumour effects: implications for immunotherapy.
    Stewart TJ; Greeneltch KM; Lutsiak ME; Abrams SI
    Expert Rev Mol Med; 2007 Feb; 9(4):1-20. PubMed ID: 17284328
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Angiogenesis modulates the tumour immune response.
    Griffioen AW; Tromp SC; Hillen HF
    Int J Exp Pathol; 1998 Dec; 79(6):363-8. PubMed ID: 10319018
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Guest editorial.
    Abrams S
    Immunol Invest; 2012; 41(6-7):555-61. PubMed ID: 23017134
    [No Abstract]   [Full Text] [Related]  

  • 80. Immune escape mechanisms as a guide for cancer immunotherapy.
    Beatty GL; Gladney WL
    Clin Cancer Res; 2015 Feb; 21(4):687-92. PubMed ID: 25501578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.